Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Sapna Syngal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5487-7471; OpenAlex author ID A5079620607; NIH RePORTER profile ID 2797726. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 1, last author 6)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
1
Collaborators
139
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 grant · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: 5 papers, 1 trial · 2020: 2 papers · 2021: 6 papers, 1 grant · 2022: 1 paper, 2 grants · 2023: 1 trial · 2024: 3 papers · 2025: 1 paper

Papers 29

  1. A Mixed-Methods Approach to Assessing Barriers and Facilitators to Cancer Genetics Care in Black and Latino/a Individuals Impacted by Pancreatic Cancer: The Ra… Last author DOI 10.1007/s10620-025-09018-7↗
  2. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  3. Expanding access to genetic testing for pancreatic cancer. First author DOI 10.1007/s10689-024-00389-w↗
  4. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Last author DOI 10.1053/j.gastro.2024.01.042↗
  5. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  6. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  7. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  8. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  9. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Last author DOI 10.1158/1940-6207.capr-20-0642↗
  10. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter Co-author DOI 10.1158/1940-6207.capr-21-0233↗
  11. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. Co-author DOI 10.1200/op.20.00678↗
  12. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  13. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  14. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗
  15. Health behaviours and beliefs in individuals with familial pancreatic cancer. Last author DOI 10.1007/s10689-019-00143-7↗
  16. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  17. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Co-author DOI 10.1038/s41588-019-0475-y↗
  18. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗
  19. Germline Genetic Testing for Pancreatic Ductal Adenocarcinoma at Time of Diagnosis. Co-author DOI 10.1001/jama.2018.6227↗
  20. Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Last author DOI 10.1002/pon.4712↗
  21. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  22. Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001165↗
  23. Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Co-author DOI 10.1158/1055-9965.epi-15-1217↗
  24. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  25. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Co-author DOI 10.1038/gim.2014.153↗
  26. Patient experiences living with pancreatic cancer risk. Last author DOI 10.1186/s13053-015-0034-1↗
  27. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Co-author DOI 10.1016/j.cgh.2012.11.016↗
  28. Identification of germline genomic copy number variation in familial pancreatic cancer. Co-author DOI 10.1007/s00439-012-1183-1↗
  29. ATM mutations in patients with hereditary pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0194↗

Trials 2

  1. InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer Principal investigator NCT05463796↗
  2. GENetic Education Risk Assessment and TEsting Study Principal investigator NCT03762590↗

Grants 4

  1. Racial/ethnic Equity in GENetic Education, Risk Assessment and TEsting (REGENERATE) Study AWARD pancan:2022-sapna-syngal-md-mph-racial-ethnic-equity-in-genetic-educatio
  2. Development and validation of clinical prediction models for the use and interpretation of multigene hereditary cancer risk assessment R01CA132829↗
  3. Racial/ethnic Equity in GENetic Education, Risk Assessment and TEsting (REGENERATE) Study AWARD pancan:2021-sapna-syngal-md-mph-racial-ethnic-equity-in-genetic-educatio
  4. The Genetics and Prevention of Gastrointestinal Cancers K24CA113433↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 19 shared papers, 2012–2025 · strength 1.74
  2. Alison P. Klein · 13 shared papers, 2012–2024 · strength 1.00
  3. Nicolette Juliana Rodriguez · 4 shared papers, 2021–2025 · strength 0.92
  4. Randall E. Brand · 10 shared papers, 2016–2024 · strength 0.89
  5. Elena M. Stoffel · 10 shared papers, 2016–2024 · strength 0.89
  6. Ralph H. Hruban · 12 shared papers, 2012–2024 · strength 0.85
  7. Gloria M. Petersen · 12 shared papers, 2012–2024 · strength 0.85
  8. Marcia Irene Canto · 9 shared papers, 2013–2024 · strength 0.81
  9. Fay Kastrinos · 7 shared papers, 2019–2024 · strength 0.73
  10. Meghan L. Underhill-Blazey · 6 shared papers, 2015–2024 · strength 0.65
  11. Anirban Maitra · 4 shared papers, 2018–2025 · strength 0.55
  12. Matthew B.B. Yurgelun · 5 shared papers, 2019–2024 · strength 0.54
  13. Steve Gallinger · 9 shared papers, 2012–2021 · strength 0.52
  14. James J. Farrell · 4 shared papers, 2020–2024 · strength 0.47
  15. Barbara J. Kenner · 3 shared papers, 2021–2025 · strength 0.46
  16. Tara B. Coffin · 3 shared papers, 2021–2025 · strength 0.46
  17. Anil K. Rustgi · 5 shared papers, 2016–2024 · strength 0.43
  18. C. Sloane Furniss · 3 shared papers, 2018–2024 · strength 0.41
  19. Bryson W. Katona · 3 shared papers, 2021–2024 · strength 0.39
  20. Kari G. Rabe · 6 shared papers, 2012–2021 · strength 0.37
  21. Anne Marie Lennon · 4 shared papers, 2013–2024 · strength 0.35
  22. Jeanin Elise van Hooft · 4 shared papers, 2019–2022 · strength 0.33
  23. Marco J. Bruno · 4 shared papers, 2019–2022 · strength 0.33
  24. Aimee Lee Lucas · 4 shared papers, 2019–2022 · strength 0.33
  25. Nicholas Jason Roberts · 6 shared papers, 2012–2021 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.